MORGAN STANLEY PLC/CALL/BIOGEN IDEC/270/0.01/20.09.24

MORGAN STANLEY PLC/CALL/BIOGEN IDEC/270/0.01/20.09.24 Share Price

DE000MG6CDJ5

Market Closed - Börse Stuttgart 12:19:08 12/07/2024 am IST
0.045 ^EUR	+15.38%

Current month

+4.65%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BIOGEN INC.

Chart MORGAN STANLEY PLC/CALL/BIOGEN IDEC/270/0.01/20.09.24

Latest news about BIOGEN INC.

BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm	11/07	BU
Eisai Co., Ltd. - LEQEMBI Approved for the Treatment of Alzheimer's disease in Hong Kong	11/07	AQ
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331	11/07	MT
Biogen, Eisai Say Alzheimer's Drug Leqembi Secures Regulatory Approval in Hong Kong	11/07	MT

More news

Quotes 5-day view

Date	Price	Change
11/24/11	0.045	+15.38%
10/24/10	0.039	+5.41%
09/24/09	0.037	+2.78%
08/24/08	0.036	+9.09%
05/24/05	0.033	+10.00%

Delayed Quote Börse Stuttgart

Last update July 12, 2024 at 12:19 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BIOGEN INC.
Issuer	Morgan Stanley
WKN	MG6CDJ
ISIN	DE000MG6CDJ5
Date issued	20/06/2024
Strike	270 $
Maturity	20/09/2024 (71 Days)
Parity	100 : 1
Emission price	0.07 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.052 €
Lowest since issue	0.03 €
Delta	0.25x
Omega	11.02
Premium	16.5x
Gearing	43.52x
Moneyness	0.8757
Difference Strike	33.2 $
Difference Strike %	+12.30%
Spread	0.01 €
Spread %	18.18%
Theoretical value	0.0500
Implied Volatility	37.20 %
Total Loss Probability	79.63 %
Intrinsic value	0.000000
Present value	0.0500
Break even	275.43 €
Theta	-0.01x
Vega	0x
Rho	0x

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Sector

More about the company

Ratings for Biogen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Biogen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

236.8 USD

Average target price

282 USD

Spread / Average Target

+19.10%

Consensus